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Local Renal Delivery of a Natriuretic Peptide
A Renal-Enhancing Strategy for B-Type
Natriuretic Peptide in Overt Experimental Heart Failure
Horng H. Chen, MB, BCH, Alessandro Cataliotti, MD, PHD, John A. Schirger, MD,
Fernando L. Martin, MD, Lynn K. Harstad, AS, John C. Burnett, JR, MD
Rochester, Minnesota
Objectives The purpose of this study was to test the hypothesis that local renal delivery of B-type natriuretic peptide (BNP)
will overcome renal resistance to BNP without systemic hypotension.
Background BNP has vasodilating, natriuretic, and renin-inhibiting properties. In overt heart failure (HF), there is development
of renal resistance to BNP.
Methods We defined the cardiorenal and humoral effects of systemic (n  6) or local renal (n  7) administration of ca-
nine BNP (0.01 g/kg/min) in 2 separate groups of dogs with pacing-induced subacute overt HF complicated by
renal dysfunction. We used a commercially available small (3.1-F) bifurcated renal catheter (FlowMedica Inc.,
Fremont, California) for direct bilateral infusion of BNP into both renal arteries.
Results With systemic BNP at this clinically used dose (without the bolus), urine flow increased, but there was only a
trend for an increase in urinary sodium excretion and glomerular filtration rate (GFR). In contrast, local renal de-
livery of BNP resulted in significant diuresis and natriuresis and an increase in GFR. These diuretic and natri-
uretic responses were greater with local renal BNP compared with systemic BNP, and were associated with in-
creased delivery of BNP to the renal tubules as evident by a greater urinary BNP excretion resulting in a
decrease in distal reabsorption of sodium. Importantly, local renal BNP did not result in a significant decrease in
mean arterial pressure that was observed with systemic BNP.
Conclusions We conclude that local renal BNP delivery is a novel strategy that may overcome renal assistance to BNP in
overt HF by increasing local delivery of BNP to the renal tubules. (J Am Coll Cardiol 2009;53:1302–8) © 2009
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.030r
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s-type natriuretic peptide (BNP) is a 32-amino acid peptide
ith vasodilating natriuretic, diuretic, lusitropic, growth-
uppressing, and anti-inflammatory properties (1,2). Unlike
onventional diuretic agents, BNP may preserve or enhance
he glomerular filtration rate (GFR) and suppress plasma
enin release (3–6). In 2 recent placebo-controlled clinical
rials involving patients undergoing cardiovascular surgery
ith either left ventricular dysfunction or chronic renal
nsufficiency, intravenously administered BNP enhanced
enal function (7,8). Although BNP has demonstrated
rom the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases,
epartment of Internal Medicine, Mayo Clinic College of Medicine, Rochester,
innesota. This research was supported by FlowMedica Inc. However, this is an
nvestigator-initiated study, and the sponsor had no role in the design of the study and
nalysis of the data. Drs. Chen and Burnett have received honoraria and research
rants from FlowMedica Inc. and Scios Inc. Drs. Chen and Burnett have patented
nd received royalties for designer natriuretic peptides. Dr. Chen has received royalties
rom Uptodate Inc. Mayo Clinic has patented and licensed designer natriuretic
eptides.p
Manuscript received April 28, 2008; revised manuscript received December 1,
008, accepted January 5, 2009.enal-enhancing actions in humans and animal models of
eart failure (HF), the renal response may also be markedly
ttenuated or even absent, underscoring a renal resistance to
NP in some patients or under certain experimental con-
itions (9,10). Furthermore, analysis of clinical trials with
NP in human HF has even suggested a worsening of renal
unction (11).
Mechanisms that limit the renal actions of the natriuretic
eptides in overt HF may be linked to humoral and
emodynamic factors. Our group and others have recently
eported data in overt experimental HF that phosphodies-
erase V (PDEV) inhibition may enhance the renal response
o BNP (12). This indicates that PDEV activity, which
egrades BNP-mediated generation of its second messenger
=,5= cyclic guanosine monophosphate (cGMP), may limit
he full renal actions of BNP in overt HF. Another
mportant braking action on the renal actions of the natri-
retic peptides is renal perfusion pressure. Specifically,
tudies have clearly demonstrated that a reduction in renal
erfusion pressure by supra-aortic constriction in experi-
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April 14, 2009:1302–8 Local Renal Delivery of BNPental studies in canines blunts the renal response to
atriuretic peptide administration (13). This concept of the
mportance of renal perfusion pressure is underscored in
uman HF in a retrospective study of patients hospitalized
ith acute HF and hypotension whose renal function im-
roved in response to infusion of nonhypotensive doses of
NP (14).
The goal of the current study was to test the hypothesis
hat increasing the local renal delivery of BNP directly into
he kidney, avoiding systemic hypotension and reductions in
enal perfusion pressure, would result in renal-enhancing
ctions exceeding systemic BNP administration. We tested
his hypothesis in a well-characterized canine model of
ubacute overt HF characterized by avid sodium and water
etention, marked activation of the renin-angiotensin-
ldosterone system (RAAS), severe renal vasoconstriction,
nd reductions in GFR, thus mimicking renal and neuro-
umoral characteristics of the cardiorenal syndrome. If such
n approach proved successful, it would provide insight into
ptimizing the use of a natriuretic peptide for renal dys-
unction associated with HF through local and not systemic
eptide delivery. The clinical importance of testing this
ypothesis is supported by epidemiological data from the
DHERE (Acute Decompensated Heart Failure National
egistry) study that reported that a major unmet need in the
anagement of acute decompensated HF is a pharmaco-
ogical approach to treat marked renal dysfunction, which
ccurs in at least 65% of patients hospitalized for acute HF
nd which is associated with excess mortality and morbidity
3,5).
ethods
tudies were conducted in 3 groups of anesthetized male
ongrel dogs (18 to 23 kg). The first group (n  6) were
ormal dogs that served as a reference group to characterize
ardiorenal and neurohumoral function in the absence of
F. The 2 other groups were groups with subacute overt
F produced by rapid ventricular pacing at 240 beats/min
or 10 days on a fixed sodium diet. The 2 HF groups
onsisted of a systemic delivery (systemic) group (n 6) and
local renal delivery (local) group (n  7). Studies were
erformed in accordance with the Animal Welfare Act and
ith approval of the Mayo Clinic Institutional Animal Care
nd Use Committee.
As stated above, we utilized a well-characterized model of
vert HF in canines, produced by rapid ventricular pacing.
ll HF dogs underwent implantation of a programmable
ardiac pacemaker (Medtronic, Minneapolis, Minnesota).
nder pentobarbital sodium anesthesia (30 mg/kg, intrave-
ous) and artificial ventilation (Harvard respirator, Harvard
pparatus, Millis, Massachusetts) with 5 l/min supplemen-
al oxygen, a left lateral thoracotomy, and a pericardiotomy
ere performed. With the heart exposed, a screw-in epicar-
ial pacemaker lead was implanted into the right ventricle.
he pacemaker generator was implanted subcutaneously 3nto the left chest wall and con-
ected to the pacemaker lead.
ogs received pre- and post-
perative prophylactic antibiotic
reatment with 225 mg of clinda-
ycin subcutaneous and 400,000
of procaine penicillin G plus
00 mg of dihydrostreptomy-
in intramuscularly (Combi-
tic, Pfizer, Inc., New York,
ew York). Post-operative pro-
hylactic antibiotic was contin-
ed through the first 2 post-
perative days. Dogs were fed a
xed sodium diet (58 mEq/day,
ill’s ID, Topeka, Kansas) and
llowed water ad lib. All dogs
ere walked daily. Appetite, ac-
ivity, body temperature, and
ondition of surgical skin sites
ere documented. Following a
4-day post-operative recovery
eriod, the pacemaker was turned on at 240 beats/min.
On Day 11 of rapid ventricular pacing at 240 beats/min,
n acute experiment was carried out to determine the
ardiorenal and humoral effects of systemic (n  6) or local
n  7) administration of canine BNP (0.01 g/kg/min).
n the night before experimentation, animals were fasted
nd given 300 mg of lithium carbonate for assessment of
enal tubular function. On the day of the experiment, dogs
ere anesthetized with sodium pentobarbital (15 mg/kg,
ntravenous), intubated, and mechanically ventilated with
upplemental oxygen (Harvard respirator) at 12 cycles/min.
flow-directed balloon-tipped thermodilution catheter
Ohmeda, Criticath, Madison, Wisconsin) was advanced
nto the pulmonary artery via the external jugular vein for
ardiac hemodynamic measurement. The left femoral artery
as cannulated for blood pressure monitoring and blood
ampling; the catheter was placed just below the level of the
enal arteries to allow us to estimate the concentration of
NP that is delivered to the kidneys (Fig. 1). The femoral
ein was also cannulated for inulin and normal saline
nfusion. The left kidney was exposed via a flank incision,
nd the ureter was cannulated for urine collection. A
alibrated electromagnetic flow probe was placed around the
enal artery to measure renal blood flow (RBF). In the local
roup, the FlowMedica (Fremont, California) bifurcated
nfusion catheter was inserted as under fluoroscopy, over a
.035-inch guidewire up the aorta to the renal arteries via a
ight femoral arterial access after injection of 3 ml of contrast
Visipaque, GE Healthcare, Waukesha, Wisconsin) via a
igtail catheter (Fig. 1). Fluoroscopy and direct palpation of
he exposed renal artery confirmed the position of the catheter.
The experiment began after a 60-min equilibration pe-
iod, with a 30-min baseline urinary clearance. After the
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
cGMP  3=,5= cyclic
guanosine monophosphate
CO  cardiac output
GFR  glomerular filtration
rate
HF  heart failure
MAP  mean arterial blood
pressure
PAP  pulmonary artery
pressure
PCWP  pulmonary
capillary wedge pressure
PDEV  phosphodiesterase V
RAAS  renin-angiotensin-
aldosterone system
RAP  right atrial pressure0-min baseline urinary clearance, systemic or local infusion
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Local Renal Delivery of BNP April 14, 2009:1302–8f 0.01 g/kg/min of canine BNP was started. Following a
5-min lead-in period, a 30-min clearance period was
erformed. Cardiovascular parameters measured during the
cute experiment included mean arterial blood pressure
MAP), right atrial pressure (RAP), pulmonary artery
ressure (PAP), cardiac output (CO), and pulmonary cap-
llary wedge pressure (PCWP). CO was determined by
hermodilution in triplicate and averaged (Cardiac Output
odel 9510-A computer, American Edwards Laboratories,
rvine, California). MAP was assessed via direct measure-
ent from the femoral arterial catheter. Renal perfusion
ressure was calculated as MAP  RAP in mm Hg. Inulin
as administered intravenously at the start of the equili-
ration period as a calculated bolus, followed by a 1 ml/min
ontinuous infusion to achieve plasma levels of 40 to 60
g/dl. GFR was calculated by inulin clearance.
Cardiovascular hemodynamics was measured at the start
f each clearance. Arterial blood was collected in heparin
nd EDTA tubes and immediately placed on ice midway
hrough each clearance. After centrifugation at 2,500 rpm at
°C, plasma was decanted and stored at 20°C until
Figure 1 Illustration of the Benephit CV Intrarenal Catheter
and the Infrarenal Catheter for Blood Sampling
Figure illustration by Mayo Clinic.nalysis. Urine was collected on ice during the entire period lf each clearance for assessment of urine volume, electro-
ytes, and inulin. Urine collected for cGMP analysis was
eated to more than 90°C before storage.
Plasma and urinary samples for BNP, renin, aldosterone,
ngiotensin II, and cGMP were measured by radioimmuno-
ssay using the methods previously described (12). Urinary and
lasma inulin concentrations were measured by the anthrone
ethod. Urinary and plasma lithium levels were determined by
ame emission spectrophotometry (model 357, Instrumenta-
ion Laboratory, Wilmington, Massachusetts). Employing the
ithium clearance (CLLi) technique, distal factional reabsorp-
ion of sodium (DFRNa) was calculated utilizing the following
quation: DFRNa  (CLLi  CLNa)/CLLi  100, where
LLi  (urine Li  urine flow)/plasma Li and CLNa 
urine Na  urine flow)/plasma Na.
ample size. Our sample size calculation was based on our
revious studies in the model of overt experimental HF. On
he basis of our previous experimental data, we calculated
hat a sample size of 6 to 7 animals in each group will give
s 89% power to detect a difference of 15 mm Hg in MAP,
0% power to detect a difference of 25 ml/min in GFR, 73%
ower to detect a difference of 40 Eq/min in urinary
odium excretion, and 77% power to detect a difference of
.6 ml/min in urine flow (UV). This calculation was based
n a paired t test with a significance level of p  0.05.
tatistical analysis. Results are expressed as mean  SD.
omparisons between groups were completed with a
-sample t test if the data were normally distributed or a
ilcoxon rank sum test for non-normal factors. Within-
roup measurements were compared using a paired t test for
ormally distributed differences or Wilcoxon signed rank
ests for non-normal differences. The analysis of covariance
as used to evaluate the difference between the groups,
djusting for the baseline measurements of those same
actors. Statistical significance was accepted as p  0.05.
esults
ardiorenal and humoral function in experimental overt
F at baseline. Table 1 reports cardiorenal and hormonal
unction for normal dogs (n  6) and for the overt HF
roups combined (n 13). Compared with the normal group,
he overt HF group had a significant decrease in CO and
AP associated with significant increases in cardiac filling
ressures. Renal blood flow, GFR, urinary sodium excretion,
nd UV were all significantly reduced in the overt HF group.
here was intense activation of RAAS and a strong trend for
ncreased plasma BNP levels in the overt HF group.
ardiovascular hemodynamic responses to systemic ver-
us local renal BNP delivery in experimental HF. Sys-
emic infusion of BNP resulted in a significant decrease in
AP, whereas local renal BNP infusion did not change
AP (Fig. 2). This was associated with a strong trend (p 
.07) for a decrease in renal perfusion pressure with systemic
NP, whereas renal perfusion pressure was maintained with
ocal renal BNP. At the end of the 30-min infusion period,
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April 14, 2009:1302–8 Local Renal Delivery of BNPAP and renal perfusion pressure were significantly higher
n the local renal BNP group compared with the systemic
NP group. Systemic BNP delivery significantly decreased
AP, PCWP, and PAP, which was greater compared with
ocal renal BNP delivery. Local renal BNP delivery only
esulted in a very modest decrease in PCWP and PAP
Table 2). Renal blood flow increased similarly in both
roups.
enal excretory and humoral function to systemic versus
ocal renal BNP delivery in experimental HF. Figure 3
llustrates the response in urinary sodium excretion (UNaV),
V, and GFR to systemic versus local renal BNP delivery.
Figure 2
Mean Arterial Blood Pressure
and Renal Perfusion Pressure in the
Systemic and Local BNP Delivery Groups
Open bars represent at baseline, and solid bars represent after 30 min of infu-
sion. *p  0.05 versus baseline (paired t test); †p  0.05 local BNP versus
systemic B-type natriuretic peptide (BNP) (analysis of covariance [ANCOVA]);
‡p  0.07 versus baseline (paired t test).
ardiorenal and Humoralharacteristics of Normal and Overt HF Dogs
Table 1 Cardiorenal and HumoralCharacteristics of Normal and Overt HF Dogs
Normal (n  6) Overt HF (n  13)
MAP, mm Hg 112 3 98 7*
CO, l/min 3.3 0.3 1.7 0.3*
PCWP, mm Hg 5 0.5 21 3†
RAP, mm Hg 3 0.5 11 2*
UNaV, Eq/min 69 59 3 4†
Urine flow, ml/min 0.6 0.4 0.16 0.1†
GFR, ml/min 47 20 30 11*
RBF, ml/min 240 67 152 60*
Plasma BNP, pg/ml 23 4 53 25‡
Plasma renin, ng/ml/h 3 2 20 7*
Aldosterone, ng/dl 16 12 53 31†
Angiotensin II, pg/ml 10 4 74 40*
ata are presented as mean  SD. *p  0.05 versus normal (2-sample t test); †p  0.05 versus
ormal (Wilcoxon rank sum test). ‡p  0.08 versus normal (Wilcoxon rank sum test).
BNP  B-type natriuretic peptide; CO  cardiac output; GFR  glomerular filtration rate; HF 
eart failure; MAP mean arterial blood pressure; PCWP  pulmonary capillary wedge pressure;
AP  right atrial pressure; RBF  renal blood flow; UNaV  urinary sodium excretion.nystemic BNP delivery increased UV but did not produce a
ignificant change in UNaV or GFR. In contrast, local renal
NP delivery increased UV, UNaV, and GFR significantly.
he diuretic and natriuretic actions of local renal BNP
elivery were significantly greater compared with systemic
NP delivery. These renal effects of local renal BNP
elivery were associated with increased delivery of BNP to
he kidney, as evidenced by a greater infrarenal arterial BNP
oncentration (see the Methods section) and urinary BNP
xcretion with a trend for urinary cGMP excretion to be
reater compared with systemic BNP administration (Fig.
). Local renal delivery of BNP suppressed plasma renin
ctivity (23  3 ng/ml/h to 16  3 ng/ml/h, p  0.05) and
ngiotensin II (69 36 pg/ml to 37 15 pg/ml, p 0.05),
hereas systemic BNP did not (plasma renin activity 15 
ng/ml/h to 12  5 ng/ml/h, p  0.05; angiotensin II 79
45 pg/ml to 119 144 pg/ml, p 0.05). Local BNP also
ecreased sodium reabsorption (from 99  1% to 96 
.7%, p  0.05) in the distal tubules, the site in the renal
ubules that the natriuretic peptides act on, whereas there
as only a trend for distal tubular sodium reabsorption to
ecrease (from 99  1% to 98  1.8%, p  0.4) with
ystemic BNP.
iscussion
he goal of the current study was to test the hypothesis
hat local renal delivery of BNP directly into the kidneys
ia increasing renal concentrations of BNP in the absence
f systemic hypotension would augment the renal-
nhancing actions of BNP. These studies demonstrated
hat systemic infusion of the clinical dose of BNP
without the bolus) was associated with a decrease in
lood pressure and renal perfusion pressure, and only a
rend for sodium excretion or GFR to increase. In
ontrast, local renal BNP delivery into both kidneys did
ardiovascular Hemodynamics
Table 2 Cardiovascular Hemodynamics
Baseline 0.01 g/kg/min
Systemic BNP (n  6)
MAP, mm Hg 100 8 90 10*†
CO, l/min 1.8 0.4 1.8 0.3
PAP, mm Hg 27 3 23 2†‡
PCWP, mm Hg 22 2 19 1†‡
RAP, mm Hg 11 3 9 2†‡
RBF, ml/min 138 73 153 80*
Local BNP (n  7)
MAP, mm Hg 96 6 98 4
CO, l/min 1.8 0.3 1.8 0.3
PAP, mm Hg 24 4 23 4‡
PCWP, mm Hg 20 4 19 4‡
RAP, mm Hg 10 1 9.6 0.8
RBF, ml/min 163 48 186 45*
ata are presented as mean  SD. *p  0.05 versus baseline (paired t test); †p  0.05 systemic
ersus local (analysis of covariance); ‡p  0.05 versus baseline (Wilcoxon signed rank test).
PAP  mean pulmonary arterial pressure; other abbreviations as in Table 1.ot result in a decrease in blood pressure, maintained
r
i
s
h
p
i
r
n
s
p
s
d
s
f
1306 Chen et al. JACC Vol. 53, No. 15, 2009
Local Renal Delivery of BNP April 14, 2009:1302–8enal perfusion pressure, and was associated with signif-
cant increases in urinary sodium excretion and GFR, and
uppression of the RAAS. Previous experimental studies
ave demonstrated that renal excretory function is de-
endent on renal perfusion pressure; hence, the greater
ncrease in UV and urinary sodium excretion with local
enal BNP delivery may be due in part to the mainte-
Figure 3 Urinary Sodium Excretion, Urine Flow, and Glomerular
Open bars represent at baseline, and solid bars represent after 30 min of infusion
*p  0.05 versus baseline (paired t test); †p  0.05 local B-type natriuretic pept
Figure 4 Infrarenal Arterial BNP Concentration, Urinary BNP Ex
Urinary cGMP Excretion in the Systemic and Local BN
Open bars represent at baseline, and solid bars represent after 30 min of infusion
(BNP) versus systemic BNP (rank sum test); ‡p  0.05 versus baseline (signed ra
guanosine monophosphate.ance of renal perfusion pressure. Indeed, there was a
trong trend for correlation between changes in renal
erfusion pressure and UV; however, it did not reach
tatistical significance (r  0.52, p  0.07). Despite the
ecrease in renal perfusion pressure with systemic infu-
ion of BNP, there was still an increase in UV and a trend
or sodium excretion and GFR to increase. This suggests
tion Rate in the Systemic and Local BNP Delivery Groups
P) versus systemic BNP (rank sum test).
on, and
livery Groups
0.05 versus baseline (paired t test); †p  0.05 local B-type natriuretic peptide
t); #p  0.1 local BNP versus systemic BNP (t test). cGMP  3=,5= cyclicFiltra
.
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April 14, 2009:1302–8 Local Renal Delivery of BNPhat BNP has direct action on the nephron in addition to
emodynamic actions. Indeed, previous studies have
emonstrated that BNP acts on the mesangial cells to
ncrease the glomerular ultrafiltration coefficient, which
n turn increases the GFR (15–17).
Our group and others have demonstrated in pre-clinical
tudies that the renal actions of BNP are attenuated in overt
F compared with mild HF and normal controls (18). The
echanisms that mediate the attenuated response to natri-
retic peptides in overt HF remain poorly defined and are
ost likely multifactorial. These include increased degrada-
ion of the peptide by neutral endopeptidase, decreased
umber or reduced affinity of biological receptors, or post-
eceptor events leading to reduced production of cGMP or
ncreased cGMP degradation by PDEV (10).
It is known that clearance of BNP occurs by several
outes, all of which exist within the kidneys, and these
outes include degradation by neutral endopeptidase 24.11
NEP) and clearance by NRP-C. NEP is a metalloprotease
hat is localized in greatest abundance in the kidney and
egrades the natriuretic peptides. It is found at highest
bundance in the proximal tubules and has been shown to
e up-regulated in overt HF (19). In the current study, the
mprovement in sodium excretion and GFR with local renal
elivery of BNP was associated with greater urinary BNP
xcretion compared with systemic infusion. This suggests
hat local renal BNP infusion delivered more BNP to the
idneys, which may have overwhelmed the different degra-
ative and clearance pathways for BNP in the kidneys, and
hus more BNP reached the glomerulus and renal tubules to
ct on the natriuretic peptide receptors found there (20).
his is further supported by the observation that only in the
ocal renal delivery group did we observe a decrease in distal
ubular sodium reabsorption, a site that is rich in natriuretic
eptide receptors.
As expected, systemic BNP delivery reduced cardiac
lling pressures in association with hypotension. Of note,
espite the lack of change in arterial pressure with local
enal delivery of BNP, there was a very modest decrease in
ardiac filling pressures, which was less than with systemic
elivery. This most likely reflects a combination of systemic
pillover and the increased natriuresis with the local renal
NP delivery.
The current study has clinical implications. The Benephit
V Infusion System (FlowMedica, Inc.) is a Food and
rug Administration 510(k)-cleared device indicated for
he infusion of physician-specified agents into the renal
rteries (21). This system is currently used in the coronary
atheterization laboratory for the direct renal infusion of
gents to the kidney to prevent contrast nephropathy. On
he basis of the findings of the current pre-clinical study, we
re conducting a pilot clinical study to assess the safety and
fficacy of intrarenal BNP infusion in HF patients with
ardiorenal syndrome.onclusions
n overt experimental HF with renal dysfunction, local renal
elivery of BNP has greater renal-enhancing effects com-
ared with systemic BNP delivery. These favorable renal
ffects include greater natriuretic and diuretic responses with
ncreases in GFR and suppression of the RAAS. These
enal-enhancing responses were associated with no change
n arterial pressure and the maintenance of renal perfusion
ressure, which we speculate also contributed to renal
esponsiveness to local delivery. We conclude that local
enal delivery of BNP is a novel strategy that may enhance
enal function in HF by increasing local delivery of BNP to
he renal glomerulus and tubules.
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